GREAT PROFITS ON OUR SHORT ON MS WALKING DRUG COMPANY ACORDA, STOCK CRUSHED ON PATENT RULING $ACOR
This post was just published on ZYX Short Sell Change Alert. ACOR is short from $48.73. The stock was halted at $20.33, down $6.44. The stock was being crushed before the halt as patents on Ampyra are invalidated. ACOR came to fame on Ampyra, a drug that marginally helps MS patients’ walking. We have a long history with shorting this stock. Before the halt the stock had fallen into the target zone of $14 to $21. 20% of the full core position size is being held. What To Do Now If the stock opens lower or right around the close before the halt,